SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma informs about board meeting

20 Jul 2026 Evaluate

With reference to its letter dated 20th July 2026, informing about the Board meeting scheduled on Thursday, 30th July 2026 to consider and take on record the unaudited financial results for the first quarter ended 30th June 2026. Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations, Ajanta Pharma has informed that, at the aforesaid Board Meeting, the Board of Directors will also consider: a. declaration of 1st interim dividend for the financial year ending 31st March 2027; and b. fixation of Wednesday, 5th August 2026 as the Record Date for the payment of interim dividend, if declared.

The above information is a part of company’s filings submitted to BSE. 

Ajanta Pharma Share Price

3484.40 12.40 (0.36%)
07-Aug-2026 14:07 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1940.00
Dr. Reddys Labs. 1166.65
Cipla 1465.70
Lupin 2356.00
Zydus Lifesciences 1108.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: